Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer

BACKGROUND: Homologous recombination deficiency (HRD) is shown to predict response to DNA-damaging therapies in patients with high-grade serous ovarian cancer (HGSOC); however, changes in HRD during progression remains unknown. METHODS: HRD scores were evaluated in paired primary and/or recurrent HG...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Cancer
Auteurs principaux: Patel, Jai N., Braicu, Ioana, Timms, Kirsten M., Solimeno, Cara, Tshiaba, Placede, Reid, Julia, Lanchbury, Jerry S., Darb-Esfahani, Silvia, Ganapathi, Mahrukh K., Sehouli, Jalid, Ganapathi, Ram N.
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6219476/
https://ncbi.nlm.nih.gov/pubmed/30318511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0268-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires